Your browser doesn't support javascript.
loading
Inhibition of ketohexokinase in adults with NAFLD reduces liver fat and inflammatory markers: A randomized phase 2 trial.
Kazierad, David J; Chidsey, Kristin; Somayaji, Veena R; Bergman, Arthur J; Birnbaum, Morris J; Calle, Roberto A.
Affiliation
  • Kazierad DJ; Pfizer Inc., Worldwide Research, Development, and Medicine, Cambridge, MA 02139, USA.
  • Chidsey K; Pfizer Inc., Worldwide Research, Development, and Medicine, Cambridge, MA 02139, USA.
  • Somayaji VR; Pfizer Inc., Worldwide Research, Development, and Medicine, Cambridge, MA 02139, USA.
  • Bergman AJ; Pfizer Inc., Worldwide Research, Development, and Medicine, Cambridge, MA 02139, USA.
  • Birnbaum MJ; Pfizer Inc., Worldwide Research, Development, and Medicine, Cambridge, MA 02139, USA.
  • Calle RA; Pfizer Inc., Worldwide Research, Development, and Medicine, Cambridge, MA 02139, USA. Electronic address: roberto.a.calle@pfizer.com.
Med ; 2(7): 800-813.e3, 2021 07 09.
Article in En | MEDLINE | ID: mdl-35590219
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Non-alcoholic Fatty Liver Disease / Fructokinases Type of study: Clinical_trials / Prognostic_studies Limits: Humans Language: En Journal: Med Year: 2021 Document type: Article Affiliation country: United States Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Non-alcoholic Fatty Liver Disease / Fructokinases Type of study: Clinical_trials / Prognostic_studies Limits: Humans Language: En Journal: Med Year: 2021 Document type: Article Affiliation country: United States Country of publication: United States